MX2020009130A - Anticuerpos terapéuticos anti-spla2-gib y los usos de los mismos. - Google Patents

Anticuerpos terapéuticos anti-spla2-gib y los usos de los mismos.

Info

Publication number
MX2020009130A
MX2020009130A MX2020009130A MX2020009130A MX2020009130A MX 2020009130 A MX2020009130 A MX 2020009130A MX 2020009130 A MX2020009130 A MX 2020009130A MX 2020009130 A MX2020009130 A MX 2020009130A MX 2020009130 A MX2020009130 A MX 2020009130A
Authority
MX
Mexico
Prior art keywords
spla2
therapeutic anti
gib
antibodies
gib antibodies
Prior art date
Application number
MX2020009130A
Other languages
English (en)
Inventor
Jacques Theze
Blanche Tamarit
Original Assignee
Diaccurate
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diaccurate filed Critical Diaccurate
Publication of MX2020009130A publication Critical patent/MX2020009130A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a anticuerpos humanos o humanizados que se unen a PLA2-GIB, a su producción y a los usos de los mismos. Estos anticuerpos muestran características ventajosas, en particular, para fines terapéuticos y de diagnóstico..
MX2020009130A 2018-03-02 2019-03-04 Anticuerpos terapéuticos anti-spla2-gib y los usos de los mismos. MX2020009130A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18305229.9A EP3533460A1 (en) 2018-03-02 2018-03-02 Therapeutic anti-spla2-gib antibodies and the uses thereof
PCT/EP2019/055255 WO2019166665A1 (en) 2018-03-02 2019-03-04 Therapeutic anti-spla2-gib antibodies and the uses thereof

Publications (1)

Publication Number Publication Date
MX2020009130A true MX2020009130A (es) 2021-01-08

Family

ID=61691417

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020009130A MX2020009130A (es) 2018-03-02 2019-03-04 Anticuerpos terapéuticos anti-spla2-gib y los usos de los mismos.

Country Status (15)

Country Link
US (1) US20210047432A1 (es)
EP (2) EP3533460A1 (es)
JP (1) JP2021515554A (es)
KR (1) KR20200138726A (es)
CN (1) CN112074292A (es)
AR (1) AR114129A1 (es)
AU (1) AU2019226674A1 (es)
BR (1) BR112020017956A2 (es)
CA (1) CA3091992A1 (es)
EA (1) EA202092085A1 (es)
IL (1) IL277007A (es)
MX (1) MX2020009130A (es)
SG (1) SG11202008044PA (es)
TW (1) TW202000230A (es)
WO (1) WO2019166665A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10894035B2 (en) 2015-08-31 2021-01-19 Diaccurate Use of indole compounds to stimulate the immune system
EP3693063A1 (en) * 2019-02-06 2020-08-12 Diaccurate Methods and compositions for treating cancer
EP3858357A1 (en) 2020-01-28 2021-08-04 Diaccurate Use of azole compounds to stimulate the immune system and as inhibitors for s-pla2gib
WO2021214039A1 (en) 2020-04-21 2021-10-28 Diaccurate Spla2hgib-binding molecules and uses thereof
WO2021239666A1 (en) 2020-05-26 2021-12-02 Diaccurate Therapeutic methods

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2116774C (en) 1991-09-19 2003-11-11 Paul J. Carter Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
CA2385347C (en) 1999-10-04 2009-12-15 Medicago Inc. Method for regulating transcription of foreign genes
BRPI0516284A (pt) 2004-09-23 2008-09-02 Genentech Inc anticorpo construìdo com cisteìna, método de selecionar anticorpos, compostos conjugados de droga-anticorpo, composição farmacêutica, método para matar ou inibir a proliferação de células de tumor, métodos de inibir a proliferação celular e o crescimento de células de tumor, artigo manufaturado e método para produzir um composto
EP1966169A2 (en) * 2005-12-29 2008-09-10 Immupharma France SA Compositions and methods for the inhibition of phospholipase a2
EP2581388A1 (en) * 2011-10-14 2013-04-17 Centre National de la Recherche Scientifique (CNRS) Anti-sPLA2-V antibodies and uses thereof
US9657109B2 (en) * 2012-11-02 2017-05-23 Wisconsin Alumni Research Foundation Compositions and methods for the treatment of systemic inflammatory response syndromes
EP2960252A1 (en) 2014-06-26 2015-12-30 Institut Pasteur Phospholipase for treatment of immunosuppression

Also Published As

Publication number Publication date
IL277007A (en) 2020-10-29
EP3533460A1 (en) 2019-09-04
TW202000230A (zh) 2020-01-01
CN112074292A (zh) 2020-12-11
WO2019166665A1 (en) 2019-09-06
KR20200138726A (ko) 2020-12-10
US20210047432A1 (en) 2021-02-18
BR112020017956A2 (pt) 2020-12-22
AR114129A1 (es) 2020-07-22
CA3091992A1 (en) 2019-09-06
EA202092085A1 (ru) 2021-02-09
JP2021515554A (ja) 2021-06-24
EP3758743A1 (en) 2021-01-06
AU2019226674A1 (en) 2020-09-17
SG11202008044PA (en) 2020-09-29

Similar Documents

Publication Publication Date Title
CY1122840T1 (el) Ανθρωποποιημενα ή χιμαιρικα αντισωματα cd3
CO2019014414A2 (es) Moléculas de anticuerpo que se unen a cd73 y usos de las mismas
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
MX2020009130A (es) Anticuerpos terapéuticos anti-spla2-gib y los usos de los mismos.
ECSP18041833A (es) Anticuerpos que se unen específicamente a pd-1 y sus usos
NI202000089A (es) Anticuerpos anti-cd3 y usos de estos
CO2017013356A2 (es) Anticuerpos de factor xi
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
PE20210488A1 (es) Anticuerpos especificos para gucy2c y sus usos
PE20171041A1 (es) Inmunoglobulinas hetero-dimericas de redireccionamiento de celulas t cd3/cd38 y sus metodos de produccion
CU24427B1 (es) Moléculas de anticuerpo que se unen a tim-3
EA201791485A1 (ru) Анти-cd47-антитела и их применения
PE20181367A1 (es) Anticuerpos agonistas que se unen especificamente a cd40 humana y metodos de uso
CL2019000799A1 (es) Anticuerpos y fragmentos de los mismos que se unen al receptor cannabinoide 1 (cb1) humano. (divisional solicitud 201602433)
CO2020013089A2 (es) Anticuerpos contra mica y/o micb y sus usos
UY37030A (es) Anticuerpos dirigidos a cd32b y métodos de uso de los mismos
CL2021000258A1 (es) Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos.
UY37598A (es) Anticuerpos miméticos de fgf21 y usos de los mismos
CO2018004569A2 (es) Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano
CO2020014343A2 (es) Anticuerpos específicos para cd3 y sus usos
CU20170012A7 (es) Anticuerpos anti proteína similar a angiopoyetina 4
UY36261A (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
CL2018001661A1 (es) Moléculas de anticuerpo que se unen a tnf alfa
AR113343A1 (es) ANTICUERPO MONOCLONAL ANTI-IL-5Ra
AR117578A1 (es) Anticuerpos específicos para cd3 y sus usos